<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2021.112096</article-id><article-id pub-id-type="publisher-id">ACM-40607</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20210200000_35287760.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  补体系统在膜性肾病发病机制中的研究进展
  Advances in the Study of Complement System in Pathogenesis of Membranous Nephropathy
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>谭</surname><given-names>力文</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>墨</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib></contrib-group><aff id="aff2"><addr-line>重庆医科大学附属儿童医院肾内科，儿童发育疾病研究教育部重点实验室，国家儿童健康与疾病临床医学研究中心，儿童发育重大疾病国家国际科技合作基地重庆，儿科学重庆市重点实验室，重庆</addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>05</day><month>02</month><year>2021</year></pub-date><volume>11</volume><issue>02</issue><fpage>662</fpage><lpage>668</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    膜性肾病是成人肾病综合征最常见的病理类型之一，在儿童中的发病率也逐年升高，其典型病理表现为肾小球脏层上皮细胞下免疫复合物沉积。免疫复合物可激活补体系统，最终形成膜攻击复合物，导致肾脏损伤。目前关于补体系统在膜性肾病的发病机制中的具体作用不详，本文将从动物实验、补体系统激活、补体系统调节等几方面阐述膜性肾病的发病机制研究进展。
    Membranous nephropathy is one of the most common pathological types of nephrotic syndrome in adults, and the incidence of membranous nephropathy is increasing in recent years. The typical pathological manifestation of membranous nephropathy is immune complex deposition under the podocyte cells. The immune complex activates the complement system and forms the membrane attack complex. Finally, the membrane attack complex leads to kidney injury. At present, the specific role of the complement system in the pathogenesis of membranous nephropathy is unknown. This article will discuss the advances in the study of the complement system in the pathogenesis of membranous nephropathy from animal experiments, complement system activation, and complement system regulation. 
  
 
</p></abstract><kwd-group><kwd>补体系统，膜性肾病，发病机制, Complement System</kwd><kwd> Membranous Nephropathy</kwd><kwd> Pathogenesis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>摘要</title><p>膜性肾病是成人肾病综合征最常见的病理类型之一，在儿童中的发病率也逐年升高，其典型病理表现为肾小球脏层上皮细胞下免疫复合物沉积。免疫复合物可激活补体系统，最终形成膜攻击复合物，导致肾脏损伤。目前关于补体系统在膜性肾病的发病机制中的具体作用不详，本文将从动物实验、补体系统激活、补体系统调节等几方面阐述膜性肾病的发病机制研究进展。</p></sec><sec id="s2"><title>关键词</title><p>补体系统，膜性肾病，发病机制</p></sec><sec id="s3"><title>Advances in the Study of Complement System in Pathogenesis of Membranous Nephropathy</title><p>Liwen Tan, Mo Wang<sup>*</sup></p><p>Department of Nephrology, Children’s Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, National Clinical Research Center for Child Health and Disorders, China International Science and Technology Cooperation Base of Child Development and Critical Disorders, Chongqing Key Laboratory of Pediatrics, Chongqing</p><p><img src="//html.hanspub.org/file/35-1571951x4_hanspub.png" /></p><p>Received: Jan. 17<sup>th</sup>, 2021; accepted: Feb. 2<sup>nd</sup>, 2021; published: Feb. 25<sup>th</sup>, 2021</p><p><img src="//html.hanspub.org/file/35-1571951x6_hanspub.png" /></p></sec><sec id="s4"><title>ABSTRACT</title><p>Membranous nephropathy is one of the most common pathological types of nephrotic syndrome in adults, and the incidence of membranous nephropathy is increasing in recent years. The typical pathological manifestation of membranous nephropathy is immune complex deposition under the podocyte cells. The immune complex activates the complement system and forms the membrane attack complex. Finally, the membrane attack complex leads to kidney injury. At present, the specific role of the complement system in the pathogenesis of membranous nephropathy is unknown. This article will discuss the advances in the study of the complement system in the pathogenesis of membranous nephropathy from animal experiments, complement system activation, and complement system regulation.</p><p>Keywords:Complement System, Membranous Nephropathy, Pathogenesis</p><disp-formula id="hanspub.40607-formula58"><graphic xlink:href="//html.hanspub.org/file/35-1571951x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2021 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/35-1571951x8_hanspub.png" /> <img src="//html.hanspub.org/file/35-1571951x9_hanspub.png" /></p></sec><sec id="s5"><title>1. 引言</title><p>膜性肾病(Membranous nephropathy, MN)是一种可起源于各年龄阶段的免疫性肾小球疾病，其在成人肾病综合征最常见的病理类型之一，在儿童较为少见，但其在国内发病率也在逐渐升高，可达到5%~10% [<xref ref-type="bibr" rid="hanspub.40607-ref1">1</xref>]。MN唯一诊断标准是肾脏病理活检，其典型病理表现为肾小球基底膜不规律增厚，以及免疫沉积物在肾小球毛细血管壁的上皮下靠近足细胞的地方堆积，从而引起膜样增厚。免疫复合物主要由IgG组成，在原发性膜性肾病中，IgG沉积以IgG4亚型最常见；在继发性膜性肾病中，IgG沉积以IgG1，IgG2和IgG3最为常见。免疫复合物进一步激活补体系统，形成膜攻击复合物(membrane attack complex, MAC)，进而导致肾小球，尤其是足细胞受损 [<xref ref-type="bibr" rid="hanspub.40607-ref2">2</xref>]。</p><p>补体沉积在膜性肾病中很常见，三条激活途径均可在膜性肾病中观察到 [<xref ref-type="bibr" rid="hanspub.40607-ref3">3</xref>]。最新研究发现，肾小球C3高强度沉积组的患者发生肾衰竭的风险更高，C3在肾小球的高强度沉积可以作为膜性肾病患者肾衰竭的预测指标 [<xref ref-type="bibr" rid="hanspub.40607-ref4">4</xref>]。尿MAC与疾病活动和预后相平，尿MAC可以作为免疫学缓解和复发的标志。因而，对于补体系统在膜性肾病中的发病机制的研究是具有重要意义的。目前膜性肾病具体发病机制不详，我们将对补体系统在膜性肾病发病机制中的研究进展进行综述。</p></sec><sec id="s6"><title>2. 补体系统的生物学基础</title><p>补体系统由超过50种可精确调控的蛋白质组成，是人体固有免疫的重要部分，且是联通固有免疫和获得性免疫的桥梁 [<xref ref-type="bibr" rid="hanspub.40607-ref5">5</xref>]。既往认为肝脏产生的血浆补体是参与反应的主要成分，近年来的研究发现补体可以由局部组织及炎症细胞分泌，甚至部分研究显示细胞内补体可影响细胞新陈代谢，这为补体系统在肾脏疾病的研究提供了新思路 [<xref ref-type="bibr" rid="hanspub.40607-ref6">6</xref>]。由于启动步骤不同，补体激活途径分为3条，分别是经典途径(classical pathway, CP)、凝集素途径(lectin pathway, LP)和旁路途径(alternative pathway, AP)。补体经典途径通过C1q与IgM和IgG激活，其主要是与IgG1，IgG2，IgG3三种亚型的结合。通过甘露糖结合凝集素(mannose-binding lectin, MBL)/胶原样凝集素(collectin)/纤维胶凝蛋白(ficolin)与体内微生物或凋亡宿主细胞的结合，MBL相关的丝氨酸蛋白酶(MBL-associated serine protease)激活裂解C2和C4，产生C3转化酶(C4b2a)，激活补体系统。AP与CP和LP不同，没有特异性模式识别分子(pattern recognition molecules, PRMs)，C3在体内缓慢自发水解形成C3 (H<sub>2</sub>O)，这一现象也被称为低速工作(tick-over)现象。同时，AP也可以被CP、LP途径的中间产物C3b激活，三条途径共同产生的C3b在B因子和D因子作用下形成活化的C3转化酶(C3bBb)，在裂解素(properdin)保护作用下，C3bBb进一步激活补体系统，形成MAC [<xref ref-type="bibr" rid="hanspub.40607-ref2">2</xref>]。三种途径共同激活C3转化酶及C5转化酶，最终导致形成C5b-9，通常被称为膜攻击复合物，裂解微生物 [<xref ref-type="bibr" rid="hanspub.40607-ref7">7</xref>]。同时，补体系统在形成MAC过程中产生的如C3b，C3a等还可以起到调理、趋化作用，通过级联反应达到扩大炎症反应、调节机体免疫及介导凋亡细胞清除的目的 [<xref ref-type="bibr" rid="hanspub.40607-ref8">8</xref>]。近期研究通过使用电子冷冻显微镜和闪烁光谱两种方法来直接观察MAC破坏模型结构的过程，其中C6和C7与外部小叶相连并减少了膜弯曲的能量，而C8和C9穿过双层增加了膜的刚度 [<xref ref-type="bibr" rid="hanspub.40607-ref9">9</xref>]。MAC在多个研究中被发现可在人类膜性肾病中沉积 [<xref ref-type="bibr" rid="hanspub.40607-ref10">10</xref>]，由于其性质的特殊性，MAC可共价附着或合并到质膜上，因此被固定在激活位点上，可以通过免疫组化检测到。</p></sec><sec id="s7"><title>3. 动物实验</title><p>自发现1959年发现以来，小鼠海曼肾炎(Heymann nephritis, HN)模型作为膜性肾病的动物实验模型，很好的模拟了膜性肾病在临床病理特征及发病机制 [<xref ref-type="bibr" rid="hanspub.40607-ref11">11</xref>]。在被动型HN小鼠模型中，有研究通过注射抗近端小管刷状缘抗体，与小鼠足细胞特异性抗原Megalin结合，形成免疫复合物，进一步激活补体系统，诱导补体介导的细胞依赖性蛋白尿 [<xref ref-type="bibr" rid="hanspub.40607-ref12">12</xref>]。同时，为了评价MAC在HN中的作用，研究者运用补体缺乏血浆灌注离体肾脏系统，发现并没有蛋白尿产生，这表明了补体系统在小鼠MN的必要性。MAC插入在免疫复合物及足细胞细胞膜上，足细胞通过内吞作用将MAC转运到肾小球上皮细胞中，然后通过尿液排除。这种细胞机制减少了细胞膜内插入的MAC积累 [<xref ref-type="bibr" rid="hanspub.40607-ref13">13</xref>]。但是另一方面，胞内MAC调控一系列的下游途径，通过蛋白激酶、脂质代谢、活性氧、生长因子/基因转录、内质网应激和泛素–蛋白酶体系统，进而影响细胞骨架和狭缝膜蛋白的完整性，导致膜性肾病 [<xref ref-type="bibr" rid="hanspub.40607-ref14">14</xref>]。在主动型HN大鼠模型中，补体系统也可以被激活。补体受体1相关蛋白/基因y (complement receptor 1-related protein/gene y, Crry)是啮齿动物中补体激活时关键的细胞调节剂。B Schiller等发现在主动型HN中，通过注射抗Crry抗体，大鼠肾脏会出现IgG沉积，但是不会出现C3及MAC的沉积，也不会出现蛋白尿 [<xref ref-type="bibr" rid="hanspub.40607-ref15">15</xref>]。这一研究在说明小鼠模型补体激活需要Crry时，也同时可以说明补体激活是蛋白尿的产生的重要因素。C5b-9的在大鼠肾小球沉积是明确的，且对于其蛋白尿产生有着重大意义，但受限于大鼠肾小球IgG亚型分型尚不明确，具体上游激活途径尚未明确。近些年来，S Timothy Spicer等研究者发现在C6缺乏型大鼠中，虽然无MAC沉积，但仍有蛋白尿产生 [<xref ref-type="bibr" rid="hanspub.40607-ref16">16</xref>]。这对补体体统，尤其是MAC在膜性肾病的发病机制的重要性发起了挑战，提示我们在形成MAC复合物之前释放的早期补体也可能参与膜性肾病的发病。</p><p>海曼肾炎小鼠模型在人类膜性肾病发病机制研究中仍有其局限性。一方面，Megalin作为HN的特异性抗原，并不在人体内表达，另一方面，M型磷脂酶A2受体(phospholipase A2 receptor, PLA2R)作为人类膜性肾病最常见的足细胞特异性抗原，不在啮齿类动物中表达，这对MN的发病机制的转化研究造成了困扰。近年来，受益于转基因技术的发展，有研究生成了在足细胞中表达鼠全长PLA2R的转基因小鼠品系。此外，通过高分辨率共聚焦显微镜观察，鼠PLA2R的表达没有引起足细胞任何形态学紊乱，足突正常。在功能学方面，将兔抗PLA2R抗体转移至小鼠体内，会引起肾病范围蛋白尿，高胆固醇血症和膜性肾病的组织形态学体征 [<xref ref-type="bibr" rid="hanspub.40607-ref17">17</xref>]。</p></sec><sec id="s8"><title>4. 补体激活</title><sec id="s8_1"><title>4.1. 经典途径</title><p>通过C1q与IgM和IgG的结合，补体经典途径被激活。C1q沉积在成人PMN并不常见，更多的认为是在SMN出现，如狼疮性肾炎的“满堂亮”现象。近期有国内学者发现C1q可在PMN中沉积 [<xref ref-type="bibr" rid="hanspub.40607-ref18">18</xref>]，国外也有研究者发现C1q可在PMN中沉积 [<xref ref-type="bibr" rid="hanspub.40607-ref19">19</xref>]。C1q更常见于由中性肽链内切酶(neutral endopeptidase, NEP)引起的新生儿期MN。母体NEP缺失产生的抗NEP IgG与胎儿足细胞表达的NEP结合形成免疫复合物导致肾脏损伤。不同亚型的IgG也会导致预后不同，通过不同病例对比，Vivarelli M等研究者发现抗NEP IgG1是导致新生儿期MN必不可少的，而抗NEP IgG4仅会导致的一过性肾脏损害，同时他们也在新生儿期MN中观察到了C1q和MAC沉积 [<xref ref-type="bibr" rid="hanspub.40607-ref20">20</xref>]。</p><p>IgG1和IgG4是MN中最常见的抗体沉积种类，IgG以六聚体形式与C1q结合激活补体系统，既往认为IgG4并不能通过经典途径激活补体系统，但后续又有研究发现在高抗原表位及补体浓度下，IgG4与抗原结合后可激活补体系统并介导末端补体复合物的形成 [<xref ref-type="bibr" rid="hanspub.40607-ref3">3</xref>]，并且由于MN中的抗体沉积并不单一，在IgG4沉积时合并有其他IgG亚型沉积，具体激活经典途径的IgG亚型还有待商榷，或许可以通过对IgG亚型进行纯化后，在进行体外验证，这有待进一步的研究。</p></sec><sec id="s8_2"><title>4.2. 凝集素途径</title><p>LP及CP的共同中间产物C4d在MN中阳性率高，而C1q在MN中阳性率不高，因此，研究LP在MN中的发病机制也是至关重要。近年来，PLA2R及1型血小板反应蛋白7A域(thrombospondin domain-containing 7A, THSD7A)作为足细胞特异性抗原，在膜性肾病的发病机制中的起着重要作用，其中PLA2R由于有着更高的阳性率，更受研究者们的关注。PLA2R及THSD7A作为内源性抗原，在参与MN的发病机制中也常与LP联系起来。作为补体激活的上游途径，MBL沉积在内源性抗原相关MN中被观察到 [<xref ref-type="bibr" rid="hanspub.40607-ref10">10</xref>]，同时MBL缺乏的MN患者肾脏活检标本中C4d仅呈现为弱染色 [<xref ref-type="bibr" rid="hanspub.40607-ref21">21</xref>]，提示这MBL在通过LP中的重要性。国内一项研究也显示在PLA2R相关的MN中，LP途径被激活 [<xref ref-type="bibr" rid="hanspub.40607-ref22">22</xref>]。C4d作为凝集素途径激活补体系统的中间产物，在MN中的阳性率极高，最高者阳性率达100%，同时MAC沉积也在由同一研究中被观察到 [<xref ref-type="bibr" rid="hanspub.40607-ref10">10</xref>]。通过MBL/MASP-C4d-MAC整条通路，合理的解释了LP在MN发病中的贡献，但是体内激活LP的初始阶段仍然有待进一步研究。IgG4是MN主要的IgG亚型 [<xref ref-type="bibr" rid="hanspub.40607-ref23">23</xref>]，同时IgG4作为PLA2R的特异性抗体，其在肾小球与PLA2R共沉积，可能起到了激活LP的作用。体外研究显示IgG4抗PLA2R自身抗体可以结合甘露聚糖结合凝集素(MBL)并激活凝集素补体途径 [<xref ref-type="bibr" rid="hanspub.40607-ref24">24</xref>]。George Haddad等人发现，在原发性膜性肾病患者中半乳糖缺陷型IgG4水平升高，抗PLA2R的IgG4抗体以糖基化依赖的方式直接结合甘露糖结合凝集素，诱导足细胞骨架蛋白水解，进而激活C5b-9补体复合体末端的组装和补体受体C3aR1或C5aR1，导致补体系统的激活 [<xref ref-type="bibr" rid="hanspub.40607-ref25">25</xref>]。</p></sec><sec id="s8_3"><title>4.3. 旁路途径</title><p>AP对肾脏影响的研究更常见于C3肾病，在膜性肾病中也有部分研究。在Florina Olaru等人的动物模型研究中发现 [<xref ref-type="bibr" rid="hanspub.40607-ref26">26</xref>]，通过人α3胶原重组非胶原域诱导小鼠产生类似于人类IgG4的抗体会引起AP的激活，在小鼠模型上表现出类似膜性肾病的改变，而在B因子缺乏的小鼠模型中，肾脏仍有类似的IgG沉积，却并不会出现蛋白尿及C5b-9的沉积，表明替代途径对于肾小球上皮下免疫复合物激活致病性补体是必需的。在人体研究中，Ravindran等研究者通过激光显微解剖及质谱分析，对MN患者进行补体蛋白组学分析，发现了LP的关键因素B因子和备解素 [<xref ref-type="bibr" rid="hanspub.40607-ref3">3</xref>]。既往认为在PLA2R相关的膜性肾病中，IgG4激活凝集素途径，但Bally等人发现了在MBL缺陷的MN患者的肾脏活检标本中由强染色的B因子、备解素及MAC，以及C1q，C4d和IgG1的染色非常弱。通过进一步的对77例原发性膜性肾病患者进行遗传测序，确定了4例MBL2启动子和编码区变异导致的MBL缺乏相关的患者，其免疫沉积物中的补体模式与首先发现的患者相同 [<xref ref-type="bibr" rid="hanspub.40607-ref21">21</xref>]。因此，补体系统可以通过旁路途径在MBL缺乏患者体内激活，进而导致膜性肾病。</p></sec></sec><sec id="s9"><title>5. 补体调节</title><p>补体的激活在正常生理情况下受到抑制，以防止其对自身细胞的损害，这一过程受到补体调节蛋白限制。每一条途径都有特定抑制剂，如H因子可阻断AP，MBL相关蛋白44 (MBL-associated protein 44, MAp44)可阻断LP，C1抑制因子补体2受体抑制剂(Complement C2 receptor inhibitor trispan ning, CRIT)和C4结合蛋白可阻断CP [<xref ref-type="bibr" rid="hanspub.40607-ref27">27</xref>]。肾小球上可表达一系列的膜结合的补体调节蛋白，如补体受体1 (complement receptor 1, CR1)、衰变加速因子(decay-accelerating factor, DAF)、膜辅助因子蛋白(membrane cofactor protein, MCP)及CD59。C1抑制因子可在CP和LP激活阶段，抑制C1r，C1s及MASP活性 [<xref ref-type="bibr" rid="hanspub.40607-ref28">28</xref>]。C3/C5转化环节作为补体系统的核心环节及三条通路的汇总阶段，受多种补体调节蛋白的调控。我们将对各补体调节蛋白的在膜性肾病的作用进行阐述。</p><sec id="s9_1"><title>5.1. CRIT</title><p>CRIT通过结合人补体蛋白C2并阻断补体激活的经典途径，从而保护细胞免受补体攻击，CRIT蛋白仅在足细胞中表达，在肾小管管周和肾小球毛细血管中不表达。有研究发现，在膜性肾病中的足细胞中观察到CRIT的均一且显着上调，在研究的其他肾病中未观察到此特异性变化 [<xref ref-type="bibr" rid="hanspub.40607-ref29">29</xref>]。MN中足细胞CRIT的表达上调，这与已知的足细胞补体受体1的丢失形成强烈反差，意味着其可能是针对MN中补体活化导致细胞损害时，机体的自我保护调节。</p></sec><sec id="s9_2"><title>5.2. DAF</title><p>DAF作为一种膜蛋白，可加速细胞表面组装的经典途径和替代途径C3和C5转化酶的衰变，从而抑制补体在C3和C5水平上的活化，最终抑制补体在细胞表面的级联扩增，并保护细胞免受补体的破坏。正常情况下，DAF存在于大多数内皮细胞中，而在MN患者中，其上皮细胞DAF mRNA表达上调，进一步的通过对C3 mRNA进行检测，发现肾小球细胞C3 mRNA/DAF mRNA比值与肾小球损伤程度有关 [<xref ref-type="bibr" rid="hanspub.40607-ref30">30</xref>]。</p></sec><sec id="s9_3"><title>5.3. CRI</title><p>CRI作为一种膜蛋白，在红细胞、单核细胞、B淋巴细胞及部分T淋巴细胞等多种循环细胞中存在，在肾脏组织中，CRI特异性表达于足细胞中。作为补体调节蛋白，CRI可以与C3b、C4b等多种补体成分结合。CRI作为一种辅因蛋白，可调节I因子裂解C3b和C4b的过程，促进C3b裂解生成催化活性不高的iC3b及iC3dg片段，阻断了C3和C5水平上的激活。研究发现，在包括膜性肾病的多种肾小球疾病中，CRI在足细胞中的表达水平显著降低，导致补体系统过度活化 [<xref ref-type="bibr" rid="hanspub.40607-ref31">31</xref>]。</p></sec><sec id="s9_4"><title>5.4. H因子</title><p>H因子是一种由20个区域组成的血浆糖蛋白，可通过加速C3bBb转化酶的衰变以及通过因子I催化C3b到iC3b的蛋白水解失活来抑制AP的激活，是AP的主要调节因子。Claudia Seikrit等研究者发现MN患者足突细胞表面的H因子自身抗体，其抑制补体H因子活性，可能导致替代途径的过度激活 [<xref ref-type="bibr" rid="hanspub.40607-ref32">32</xref>]。</p></sec><sec id="s9_5"><title>5.5. CD59</title><p>CD59是一种低分子量的糖基磷脂酰肌醇锚定抑制剂(glycosylphosphatidylinositol-anchored inhibitor)，通常存在于内皮细胞膜上以及肾小球和远端小管的上皮细胞上。CD59通过阻止C5b-8催化C9在细胞膜的聚合来抑制补体的裂解，可抑制细胞膜上C5b-9的形成。通过免疫荧光技术，膜性肾病患者肾小球中CD59的表达降低，同时膜性肾病患者尿液中CD59的含量与可溶性终末补体复合物SC5b-9的尿排泄相关 [<xref ref-type="bibr" rid="hanspub.40607-ref33">33</xref>]。在膜性肾病中，足细胞中的CD59脱落导致其抑制功能下降，导致补体活动的异常激活。</p></sec></sec><sec id="s10"><title>6. 小结与展望</title><p>综上所诉，免疫复合物激活补体，进而形成MAC是导致MN发病机制的核心部分。三条补体激活途径均可在MN中观察到，其具体权重不详，AP似乎起着更重要的作用，途径间的相互联系又加大了研究难度。同时，补体调节蛋白在MN中也有着异常表达，通过对补体激活及调节在MN发病机制的研究，可能可以为未来MN治疗提供新的思路及靶点，达到精准治疗的目的。</p></sec><sec id="s11"><title>文章引用</title><p>谭力文,王 墨. 补体系统在膜性肾病发病机制中的研究进展Advances in the Study of Complement System in Pathogenesis of Membranous Nephropathy[J]. 临床医学进展, 2021, 11(02): 662-668. https://doi.org/10.12677/ACM.2021.112096</p></sec><sec id="s12"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.40607-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Nie, S., He, W., Huang, T., et al. (2018) The Spectrum of Biopsy-Proven Glomerular Diseases among Children in China: A National, Cross-Sectional Survey. Clinical Journal of the American Society of Nephrolog, 13, 1047-1054.  
&lt;br&gt;https://doi.org/10.2215/CJN.11461017</mixed-citation></ref><ref id="hanspub.40607-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Reinhard, L., Stahl, R.A.K. and Hoxha, E. (2020) Is Primary Membranous Nephropathy a Complement Mediated Disease? Molecular Immunology, 128, 195-204. &lt;br&gt;https://doi.org/10.1016/j.molimm.2020.10.017</mixed-citation></ref><ref id="hanspub.40607-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">Ravindran, A., Madden, B., Charlesworth, M.C., et al. (2020) Proteomic Analysis of Complement Proteins in Membranous Nephropathy. Kidney International Reports, 5, 618-626. &lt;br&gt;https://doi.org/10.1016/j.ekir.2020.01.018</mixed-citation></ref><ref id="hanspub.40607-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Oto, O.A., Demir, E., Mirioglu, S., et al. (2021) Clinical Significance of Glomerular C3 Deposition in Primary Membranous Nephropathy. Journal of Nephrology. &lt;br&gt;https://doi.org/10.1007/s40620-020-00915-w</mixed-citation></ref><ref id="hanspub.40607-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">Hajishengallis, G., Reis, E.S., Mastellos, D.C., et al. (2017) Novel Mechanisms and Functions of Complement. Nature Immunology, 18, 1288-1298. &lt;br&gt;https://doi.org/10.1038/ni.3858</mixed-citation></ref><ref id="hanspub.40607-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Arbore, G., Kemper, C. and Kolev, M. (2017) Intracellular Complement—The Complosome—In Immune Cell Regulation. Molecular Immunology, 89, 2-9. &lt;br&gt;https://doi.org/10.1016/j.molimm.2017.05.012</mixed-citation></ref><ref id="hanspub.40607-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Walport, M.J. (2001) Complement. First of Two Parts. The New England Journal of Medicine, 344, 1058-1066.  
&lt;br&gt;https://doi.org/10.1056/NEJM200104053441406</mixed-citation></ref><ref id="hanspub.40607-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Hajishengallis, G., Kajikawa, T., Hajishengallis, E., et al. (2019) Complement-Dependent Mechanisms and Interventions in Periodontal Disease. Frontiers in Immunology, 10, 406. &lt;br&gt;https://doi.org/10.3389/fimmu.2019.00406</mixed-citation></ref><ref id="hanspub.40607-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Menny, A., Serna, M., Boyd, C.M., et al. (2018) CryoEM Reveals How the Complement Membrane Attack Complex Ruptures Lipid Bilayers. Nature Communications, 9, 5316. &lt;br&gt;https://doi.org/10.1038/s41467-018-07653-5</mixed-citation></ref><ref id="hanspub.40607-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Hayashi, N., Okada, K., Matsui, Y., et al. (2018) Glomerular Mannose-Binding Lectin Deposition in Intrinsic Antigen-Related Membranous Nephropathy. Nephrology Dialysis Transplantation, 33, 832-840.  
&lt;br&gt;https://doi.org/10.1093/ndt/gfx235</mixed-citation></ref><ref id="hanspub.40607-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Heymann, W., Hackel, D.B., Harwood, S., et al. (2000) Production of Nephrotic Syndrome in Rats by Freund’s Adjuvants and Rat Kidney Suspensions. 1951. Journal of the American Society of Nephrology, 11, 183-188.</mixed-citation></ref><ref id="hanspub.40607-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Akiyama, S., Imai, E. and Maruyama, S. (2019) Immunology of Membranous Nephropathy. F1000Research, 8, 734.  
&lt;br&gt;https://doi.org/10.12688/f1000research.17589.1</mixed-citation></ref><ref id="hanspub.40607-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Ronco, P. and Debiec, H. (2017) A Podocyte View of Membranous Nephropathy: From Heymann Nephritis to the Childhood Human Disease. Pflügers Archiv, 469, 997-1005. &lt;br&gt;https://doi.org/10.1007/s00424-017-2007-x</mixed-citation></ref><ref id="hanspub.40607-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Couser, W.G. (2017) Primary Membranous Nephropathy. Clinical Journal of the American Society of Nephrology, 12, 983-997. &lt;br&gt;https://doi.org/10.2215/CJN.11761116</mixed-citation></ref><ref id="hanspub.40607-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">Schiller, B., He, C., Salant, D.J., et al. (1998) Inhibition of Complement Regulation Is Key to the Pathogenesis of Active Heymann Nephritis. Journal of Experimental Medicine, 188, 1353-1358. &lt;br&gt;https://doi.org/10.1084/jem.188.7.1353</mixed-citation></ref><ref id="hanspub.40607-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">Salant, D.J. (2019) Unmet Challenges in Membranous Nephropathy. Current Opinion in Nephrology and Hypertension, 28, 70-76. &lt;br&gt;https://doi.org/10.1097/MNH.0000000000000459</mixed-citation></ref><ref id="hanspub.40607-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">Meyer-Schwesinger, C., Tomas, N.M., Dehde, S., et al. (2020) A Novel Mouse Model of Phospholipase A2 Receptor 1-Associated Membranous Nephropathy Mimics Podocyte Injury in Patients. Kidney International, 97, 913-919.  
&lt;br&gt;https://doi.org/10.1016/j.kint.2019.10.022</mixed-citation></ref><ref id="hanspub.40607-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, M.-F., Cui, Z., Zhang, Y.-M., et al. (2018) Clinical and Prognostic Significance of Glomerular C1q Deposits in Primary MN. Clinica Chimica Acta, 485, 152-157. &lt;br&gt;https://doi.org/10.1016/j.cca.2018.06.050</mixed-citation></ref><ref id="hanspub.40607-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">Sethi, S., Madden, B.J., Debiec, H., et al. (2019) Exostosin 1/Exostosin 2-Associated Membranous Nephropathy. Journal of the American Society of Nephrology, 30, 1123-1136. &lt;br&gt;https://doi.org/10.1681/ASN.2018080852</mixed-citation></ref><ref id="hanspub.40607-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">Vivarelli, M., Emma, F., Pellé, T., et al. (2015) Genetic Homogeneity but IgG Subclass-Dependent Clinical Variability of Alloimmune Membranous Nephropathy with Anti-Neutral Endopeptidase Antibodies. Kidney International, 87, 602-609. &lt;br&gt;https://doi.org/10.1038/ki.2014.381</mixed-citation></ref><ref id="hanspub.40607-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">Bally, S., Debiec, H., Ponard, D., et al. (2016) Phospholipase A2 Receptor-Related Membranous Nephropathy and Mannan-Binding Lectin Deficiency. Journal of the American Society of Nephrology, 27, 3539-3544.  
&lt;br&gt;https://doi.org/10.1681/ASN.2015101155</mixed-citation></ref><ref id="hanspub.40607-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">Zhang, M.-F., Huang, J., Zhang, Y.-M., et al. (2019) Complement Activation Products in the Circulation and Urine of Primary Membranous Nephropathy. BMC Nephrology, 20, 313. &lt;br&gt;https://doi.org/10.1186/s12882-019-1509-5</mixed-citation></ref><ref id="hanspub.40607-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">Wiech, T., Stahl, R.A.K. and Hoxha, E. (2019) Diagnostic Role of Renal Biopsy in PLAR1-Antibody-Positive Patients with Nephrotic Syndrome. Modern Pathology, 32, 1320-1328. &lt;br&gt;https://doi.org/10.1038/s41379-019-0267-z</mixed-citation></ref><ref id="hanspub.40607-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">Sinico, R.A., Mezzina, N., Trezzi, B., et al. (2016) Immunology of Membranous Nephropathy: From Animal Models to Humans. Clinical &amp; Experimental Immunology, 183, 157-165. &lt;br&gt;https://doi.org/10.1111/cei.12729</mixed-citation></ref><ref id="hanspub.40607-ref25"><label>25</label><mixed-citation publication-type="other" xlink:type="simple">Haddad, G., Lorenzen, J.M., Ma, H., et al. (2020) Altered Glycosylation of IgG4 Promotes Lectin Complement Pathway Activation in Anti-PLA2R1 Associated Membranous Nephropathy. Journal of Clinical Investigation.  
&lt;br&gt;https://doi.org/10.1172/JCI140453</mixed-citation></ref><ref id="hanspub.40607-ref26"><label>26</label><mixed-citation publication-type="other" xlink:type="simple">Luo, W., Olaru, F., Miner, J.H., et al. (2018) Alternative Pathway Is Essential for Glomerular Complement Activation and Proteinuria in a Mouse Model of Membranous Nephropathy. Frontiers in Immunology, 9, 1433.  
&lt;br&gt;https://doi.org/10.3389/fimmu.2018.01433</mixed-citation></ref><ref id="hanspub.40607-ref27"><label>27</label><mixed-citation publication-type="other" xlink:type="simple">Thurman, J.M. (2020) Complement and the Kidney: An Overview. Advances in Chronic Kidney Disease, 27, 86-94.  
&lt;br&gt;https://doi.org/10.1053/j.ackd.2019.10.003</mixed-citation></ref><ref id="hanspub.40607-ref28"><label>28</label><mixed-citation publication-type="other" xlink:type="simple">Mutti, M., Ramoni, K., Nagy, G., et al. (2018) A New Tool for Complement Research: Reconstituted Human Classical Complement Pathway. Frontiers in Immunology, 9, 2770. &lt;br&gt;https://doi.org/10.3389/fimmu.2018.02770</mixed-citation></ref><ref id="hanspub.40607-ref29"><label>29</label><mixed-citation publication-type="other" xlink:type="simple">Moll, S., Lange, S., Mihatsch, M.J., et al. (2006) CRIT Is Expressed on Podocytes in Normal Human Kidney and Upregulated in Membranous Nephropathy. Kidney International, 69, 1961-1968. &lt;br&gt;https://doi.org/10.1038/sj.ki.5000379</mixed-citation></ref><ref id="hanspub.40607-ref30"><label>30</label><mixed-citation publication-type="other" xlink:type="simple">Angeletti, A., Cantarelli, C., Petrosyan, A., et al. (2020) Loss of Decay-Accelerating Factor Triggers Podocyte Injury and Glomerulosclerosis. Journal of Experimental Medicine, 217, e20191699. &lt;br&gt;https://doi.org/10.1084/jem.20191699</mixed-citation></ref><ref id="hanspub.40607-ref31"><label>31</label><mixed-citation publication-type="other" xlink:type="simple">Moll, S., Miot, S., Sadallah, S., et al. (2001) No Complement Receptor 1 Stumps on Podocytes in Human Glomerulopathies. Kidney International, 59, 160-168. &lt;br&gt;https://doi.org/10.1046/j.1523-1755.2001.00476.x</mixed-citation></ref><ref id="hanspub.40607-ref32"><label>32</label><mixed-citation publication-type="other" xlink:type="simple">Seikrit, C., Ronco, P. and Debiec, H. (2018) Factor H Autoantibodies and Membranous Nephropathy. The New England Journal of Medicine, 379, 2479-2481. &lt;br&gt;https://doi.org/10.1056/NEJMc1805857</mixed-citation></ref><ref id="hanspub.40607-ref33"><label>33</label><mixed-citation publication-type="other" xlink:type="simple">Lehto, T., Honkanen, E., Teppo, A.M., et al. (1995) Urinary Excretion of Protectin (CD59), Complement SC5b-9 and Cytokines in Membranous Glomerulonephritis. Kidney International, 47, 1403-1411.  
&lt;br&gt;https://doi.org/10.1038/ki.1995.197</mixed-citation></ref></ref-list></back></article>